- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01734278
Observational Post-Authorisation Safety Study of Asenapine (Sycrest) (OBSERVA)
July 30, 2018 updated by: Professor Saad Shakir
An Observational Post-Authorisation Safety Specialist Cohort Monitoring Study (SCEM) to Monitor the Safety and Utilisation of Asenapine (Sycrest) in the Mental Health Trust Setting in England
The purpose of this observational study is to evaluate the use and short term safety of Asenapine (Sycrest) in real-life usage in the Mental Health Trust Setting in the United Kingdom(UK) National Health Service (NHS).
The study is to be carried out independently by the Drug Safety Research Unit (DSRU) in Southampton, although it is funded by Merck, the manufacturer of Sycrest.
Study Overview
Study Type
Observational
Enrollment (Actual)
1000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Staffordshire
-
Stafford, Staffordshire, United Kingdom, ST16 3SR
- South Staffordshire and Shropshire Healthcare NHS Foundation Trust
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients prescribed asenapine in a NHS Mental Health Trust in England.
Description
Inclusion Criteria:
- Patients for whom a study questionnaire containing useful information has been returned
Exclusion Criteria:
- Patients who do not provide consent
- Patients within selected institutions (for example prisons)
- Patients who commenced treatment between date of market launch (to be confirmed) and study start
- Enrolled patients for whom both the baseline and 12-week questionnaires are returned blank (contain no clinical information)
- Enrolled patients for whom the psychiatrist, designated member of clinical care team, or study facilitator from the DSRU reports that the patient did not take or was never prescribed asenapine
- Enrolled patients for whom there is evidence to suggest duplication of patients
- Enrolled patients for whom informed written or verbal notification is received by DSRU indicating that they no longer wish to participate at any stage of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Asenapine
Patients prescribed asenapine for any indication.
|
This is a non-interventional study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The incidence of selected identified risks of asenapine in the mental health care trust setting
Time Frame: 12 weeks after asenapine is first prescribed
|
12 weeks after asenapine is first prescribed
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2012
Primary Completion (Actual)
January 1, 2017
Study Completion (Actual)
January 1, 2018
Study Registration Dates
First Submitted
November 22, 2012
First Submitted That Met QC Criteria
November 26, 2012
First Posted (Estimate)
November 27, 2012
Study Record Updates
Last Update Posted (Actual)
July 31, 2018
Last Update Submitted That Met QC Criteria
July 30, 2018
Last Verified
July 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OBSERVA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Manic Disorder
-
AstraZenecaCompletedMania | Manic Disorder | Manic State | Affective Psychosis, Bipolar | Manic-Depressive Psychosis | Psychoses, Manic-DepressiveUnited States
-
Mclean HospitalStanley Medical Research InstituteCompletedSchizoaffective Disorder | Bipolar Disorder | Mania | Manic Disorder | Manic StateUnited States
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
AstraZenecaCompletedDepression, Bipolar | Affective Psychosis, Bipolar | Manic-Depressive Psychosis | Psychoses, Manic-DepressiveUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Mayo ClinicRecruiting
-
Beersheva Mental Health CenterStanley Medical Research InstituteCompleted
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/SCompletedBipolar I Disorder | Manic EpisodeUnited States, Croatia, Ukraine
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/SCompletedBipolar I Disorder | Manic EpisodeSerbia, United States, Bulgaria, Poland
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
Clinical Trials on No intervention
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
University of Dublin, Trinity CollegeCompleted
-
Hôpital Necker-Enfants MaladesUnknown
-
China Medical University HospitalUnknownIntention to Stay, Turnover Behavior
-
Medical Corps, Israel Defense ForceUnknownMusculoskeletal Disorders | Upper Extremity Pain ChronicIsrael